气道支架治疗肺气肿相关肺过度充气:BREATHE试验六个月结果
该研究汇总两项首次人体试验,评估经支气管置入自膨胀镍钛合金气道支架治疗重度肺气肿相关肺过度充气的可行性、安全性和初步疗效。残气量在3个月和6个月分别平均降低866 ml和753 ml,肺功能、生活质量、症状和运动能力均见临床意义改善。
要点
- 气道支架可连接肺气肿实质与中心支气管,缓解肺过度充气。
- 6个月内21.7%患者发生相关严重不良事件,包括肺炎10.0%和慢阻肺急性加重5.0%。
- 残气量较基线平均降低:3个月866 ml,6个月753 ml。
核心结论
- 该研究首次提供气道支架治疗肺气肿相关肺过度充气的可行性、安全性和初步结局的临床证据。
主要发现
- 6个月内21.7%患者发生至少一次相关严重不良事件,包括肺炎10.0%和慢阻肺急性加重5.0%,无气胸发生。
- 残气量较基线平均降低:3个月866 ml(95%CI 626–1,106),6个月753 ml(95%CI 512–994)。
- 肺功能、生活质量、症状和运动能力均观察到临床意义改善。
临床怎么用
- 对于重度肺气肿相关肺过度充气患者,气道支架或可作为经支气管介入治疗的选项之一,但需关注肺炎和慢阻肺急性加重风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Despite advancements in emphysema treatment, high morbidity and mortality rates highlight the need for innovative therapies. A novel self-expanding nitinol airway scaffold was designed to alleviate lung hyperinflation by connecting emphysematous parenchyma with central bronchi, releasing trapped air. Objectives: To assess the feasibility, safety, and initial outcomes of airway scaffolds in treating emphysema-related hyperinflation. Methods: We conducted a pooled analysis of two first-in-human studies (NCT05949645, NCT05854550) involving patients with heterogeneous or homogeneous emphysema treated bronchoscopically with up to three permanent airway scaffolds per lung. Measurements and Main Results: The primary outcome was safety, measured by procedure- and/or device-related serious adverse events over 6 months. Secondary outcomes were technical feasibility, pulmonary function, quality of life, symptoms, exercise capacity at 3 and 6 months, and airway patency assessment by high-resolution computed tomography. Sixty severe emphysema patients (33 female, 27 male; mean age, 66 ± 8 yr; mean residual volume percent predicted, 255 ± 47%) were included. Ninety-eight procedures were performed, and 328 airway scaffolds were successfully placed. A proportion of 21.7% of patients experienced at least one related serious adverse event within 6 months, including pneumonia (10.0%) and chronic obstructive pulmonary disease exacerbation (5.0%), but no pneumothoraxes occurred. Residual volume improved (decreased) from baseline by a mean [95% confidence interval] of 866 [626, 1,106] ml at 3 months and 753 [512, 994] ml at 6 months. Clinically meaningful improvements were further observed in spirometry, quality of life, symptoms, and exercise capacity. Conclusions: This study provides the first clinical evidence of the feasibility, safety, and initial outcomes after treatment with airway scaffolds in patients with emphysema-related hyperinflation.
引用
- Tana A, Valipour A, Ing A, et al. Airway Scaffolds for Emphysema-related Hyperinflation: Six-Month Results from the BREATHE Trial. Am J Respir Crit Care Med. 2025. PMID: 40387356. doi:10.1164/rccm.202502-0378OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。